2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Carcinoma, Non-Small-Cell Lung
36
Neoplasms
8
Lung Neoplasms
7
Neoplasm Metastasis
4
Neoplasms by Site
3
Lymphoma, Large-Cell, Anaplastic
3
Hematologic Neoplasms
3
Breast Neoplasms
3
Brain Neoplasms
3
Thyroid Neoplasms
2
Sarcoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Gastrointestinal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Solid Tumors
1
Sexual Dysfunction, Physiological
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Rare Tumour
1
Rare Tumor
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Interventions
Carboplatin
12
Paclitaxel
11
Gemcitabine
11
Capecitabine
7
Irinotecan
6
Fluorouracil
5
Cisplatin
5
Radiotherapy
4
Oxaliplatin
4
Leucovorin
4
Bevacizumab
4
pembrolizumab
3
Filgrastim
3
Etoposide
3
Erlotinib Hydrochloride
3
Cyclophosphamide
3
etoposide phosphate
2
atezolizumab
2
Trastuzumab
2
Topotecan
2
Taxes
2
Surveys and Questionnaires
2
Peripheral Blood Stem Cell Transplantation
2
Magnetic Resonance Spectroscopy
2
Genetic Testing
2
FAPI-46
2
Docetaxel
2
CP protocol
2
Amifostine
2
Albumin-Bound Paclitaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Unknown Primary
×
alectinib
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts